Amgen manufacturing warning letter
Amgen resolves manufacturing problems surrounding Kineret (anakinra) July 7, company says. FDA May 9 1warning letter cited Amgen's Boulder, Colo. manufacturing facility; infractions included lack of thorough investigation of filtered purified bulk; construction and expansion of support systems without adequate change control; failure to notify FDA of changes to production process; and exporting product not intended for export...
You may also be interested in...
Amgen is making global changes to its internal inspection procedures in response to a warning letter from FDA
President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.